Published on
October 9, 2026
- 04:18 GMT
Numiera Therapeutics Announces Repositioning of First-In-Class CPT1 Inhibitor Etomoxir for the Treatment of Glioblastoma
The company presented data on its orphan-designated lead asset to the European Association for Cancer Research Meeting in Bilbao, Spain, this week. DENVER, CO, UNITED STATES, October 8, 2026 /EINPresswire.com/ -- Numiera Therapeutics Inc. (“Numiera”), …
Distribution channels:
Banking, Finance & Investment Industry, Companies
...
